PDS Biotechnology Corp: virtual KOL event on PDS0301 Phase 2 results

What happened On Oct 6, 2026, PDS Biotechnology Corporation issued a press release announcing that the company will host a virtual key opinion leader event featuring Jonathan M. Hernandez, M.D., an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. The filing says Dr. Hernandez will join company management to discuss clinical outcomes from the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer cohort.

Key details

• Press release issued Oct 6, 2026.
• Presenter: Jonathan M. Hernandez, M.D., investigator, Surgical Oncology Program, National Cancer Institute’s Center for Cancer Research.
• Topic: clinical outcomes from PDS0301 Phase 2 trials for advanced liver-associated cancers, focused on the metastatic colorectal cancer cohort.

Why it may matter The filing reports Item 8.01 (other events), which covers the announced virtual key opinion leader event and the topics to be discussed. The filing also includes Item 9.01, which attaches the press release as an exhibit. A filing does not show why the insider traded or why the company acted.